Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Withdrawn Agents, Label Updates, and New Drug Formulations Shaped the Oncology Field in 2024

February 14th 2025

See this full list of regulatory decisions from 2024 regarding withdrawn agents, label updates, and new drug formulations.

Oncology Experts Preview Top Abstracts From 2025 ASCO GU

February 12th 2025

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Bladder Cancer Care Shifts as BCG Shortage Lingers, With Investigative Combinations and Tools at the Forefront

February 10th 2025

Vikram M. Narayan, MD, details updates in the bladder cancer field, including effects of the BCG shortage and upcoming therapies/tools of interest.

Nogapendekin Alfa Inbakicept Is Under EMA Review for BCG-Unresponsive NMIBC With CIS

January 27th 2025

The EMA has accepted for review an MAA seeking the approval of nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with CIS.

UGN-102 Shows Favorable Risk-Benefit Profile, Sustained CR Rates in Low-Grade, Intermediate-Risk NMIBC

January 22nd 2025

Durable responses with UGN-102 signal its viability as a nonsurgical alternative to TURBT in low-grade, intermediate-risk NMIBC.

Dr Garje on Unmet Needs in Small Cell Bladder Cancer

January 17th 2025

Rohan Garje, MD, discusses the unmet needs for patients with small cell bladder cancer.

Dr Lee on the Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

January 16th 2025

John K. Lee, MD, PhD, discusses the EV-302 trial of frontline enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

FDA Approval Is Sought for TAR-200 in BCG-Unresponsive High-Risk NMIBC With CIS

January 15th 2025

An NDA has been submitted to the FDA seeking the approval of TAR-200 for BCG-unresponsive high-risk NMIBC with CIS, with or without papillary tumors.

Nivolumab Plus Gemcitabine/Cisplatin Shows Favorable OS/PFS Trend in Asian Unresectable/Metastatic Urothelial Cancer Subpopulation

January 15th 2025

First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.

Sasanlimab Plus BCG Could Alter Treatment Paradigm in BCG-Naive, High-Risk NMIBC

January 14th 2025

Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Sasanlimab Plus BCG Meets EFS End Point in BCG-Naive, High-Risk NMIBC

January 10th 2025

Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Dr Lotan on the Benefits and Complications Associated With Radical Cystectomy in BCG-Unresponsive NMIBC

January 10th 2025

Yair Lotan, MD, discusses the benefits and complications associated with radical cystectomy for patients with BCG-unresponsive NMIBC.

Dr Lotan on the Future Research Directions in BCG-Unresponsive NMIBC

January 9th 2025

Yair Lotan, MD, discusses the evolving treatment paradigm for Bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer.

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC

January 9th 2025

Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.

China’s NMPA Approves Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer

January 8th 2025

Enfortumab vedotin-efjv plus has received NMPA approval for patients with locally advanced or metastatic urothelial cancer.

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

January 3rd 2025

Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.

Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer

December 20th 2024

Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

December 19th 2024

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Final Clinical Perspectives: EV+P is the New Standard of Care in Frontline Treatment of UC

December 6th 2024

Thomas Powles, MBBS, MRCP, MD, discusses how according to the ESMO guidelines, enfortumab vedotin plus pembrolizumab (EV+P) has become the new standard of first-line therapy in advanced urothelial carcinoma, and if there are patients who are ineligible for EV+P, alternatives are available such as nivolumab plus cisplatin/gemcitabine or platinum-based chemotherapy followed by maintenance avelumab.

Timeline of Enfortumab Vedotin in UC: From Previously Treated UC to Frontline Therapy

December 6th 2024

Thomas Powles, MBBS, MRCP, MD, discusses how antibody-drug conjugates have demonstrated improvement over chemotherapy. Data from the EV-301 trial shows that the antibody-drug conjugate enfortumab vedotin decreased the risk of death by 30% versus chemotherapy. Later trial data showed that treatment using enfortumab vedotin plus pembrolizumab (EV+P) reduced the risk of patient death by 53%.